Proposed Hydroquinone Ban Criticized In Literature Review
This article was originally published in The Rose Sheet
Executive Summary
Disrupting the availability of hydroquinone skin-lightening products would represent an "overreaction" by FDA, according to a literature review published in the November issue of the Journal of the American Academy of Dermatology
You may also be interested in...
Hydroquinone Marketer Ceases Shipments After Warning From Texas
Obagi Medical is ceasing shipments of hydroquinone 4% products to doctors’ offices in Texas after the state's Department of State Health Services (DSHS) warned about compliance with federal and Texas laws.
Hydroquinone Marketer Ceases Shipments After Warning From Texas
Obagi Medical is ceasing shipments of hydroquinone 4% products to doctors’ offices in Texas after the state's Department of State Health Services (DSHS) warned about compliance with federal and Texas laws.
Dermatologists Respond In Force To Proposed Ban Of OTC Skin Bleaching
Dermatologists concerned about losing over-the-counter access to skin bleaching products formulated with hydroquinone - as proposed by FDA - are counting on industry to submit compelling safety data